October 26, 2016
AstraZeneca’s ovarian cancer tablets pass Phase III SOLO-2 trial
AstraZeneca’s Lynparza tablets against BRCA-mutated ovarian cancer have shown…
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
October 25, 2016
Novartis’s Q3 2016 net income $10,9B shorter than last year
Novartis’s Q3 2016 net income $10,9B shorter than last year
October 25, 2016
Allergan completes acquisition of Vitae
Allergan successfully completed its tender offer to purchase …
October 25, 2016
Bangladesh’s Beximco gets its second US FDA product approval
Bangladesh-based Beximco, the largest country’s pharmaceutcals exporter, has received its second US FDA …
October 24, 2016
Astellas’s and Pfizer’s cancer drug gets new product label data
Astellas Pharma and Pfizer have announced the FDA approved a supplemental New …
October 24, 2016
FDA gives green light to Merck’s CDI drug
The US FDA has approved Merck’s Zinplava (bezlotoxumab) Injection 25 mg/mL, which …
October 24, 2016
Biophytis outsources AMD drug production to Patheon, USA
Biophytis has entered into an agreement with US firm Patheon for the industrial …
October 24, 2016
GSK applies to FDA for zoster vaccine
GlaxoSmithKline has submitted a Biologics License Application (BLA) for its candidate shingles vaccine, ShingrixTM, to the United States Food and Drug Administration (FDA).
October 24, 2016
Faron recruits patients for the Japanese Traumakine Phase III trial
Faron Pharmaceuticals (Faron), the clinical stage biopharmaceutical company, has recruited the first patient in the Japanese Phase III pivotal clinical trial for the…
October 21, 2016
Nanobiotix’s partner, PharmaEngine launched a new NBTXR3 clinical trial in head and neck cancers
Nanobiotixa has announced that its Asia-Pacific partner, PharmaEngine, has dosed its first patient in a new Phase I/II trial in patients with head and neck cancers patient receiving radiotherapy plus chemotherapy, this October.